Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs Visa Inc (V) Price & Performance

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs Visa Inc — how do they compare? Merck & Co., Inc. trades at $130.01 (market cap $321.77B), while Visa Inc trades at $361.98 (market cap $671.74B). The key difference: Visa Inc is far larger — about 2.1× Merck & Co., Inc.'s market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

MRKV
Market Cap
$321.77B$671.74B
Sector
HealthFinancials
52-Week High
$131.84$370.47
52-Week Low
$77.60$295.52
Enterprise Value
$368.53B$682.32B
Dividend Yield
2.61%0.74%
Volume
10,431,336

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.90, up 1.81% on the day, with a bullish technical outlook and strong institutional support. Recent earnings beats in Q4 2025 and Q1-Q2 2026, alongside a 28.07% net income margin in 2025, highlight operational strength. The acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline, though a high P/E of 104.74 signals premium valuation. Cash flow remains positive at $1.37B in 2025, but investing outflows have increased.

The stock offers growth potential from pipeline expansion and analyst consensus targeting $140.36, but risks include elevated debt-to-asset ratios (36.06% in 2025) and competitive pressures. Investors should weigh robust profitability against valuation concerns and macroeconomic headwinds affecting the pharma sector.

Visa Inc

Visa (V) trades at $361.32, down 0.33% on the day, with a bearish technical signal but strong fundamentals including a 50.78% net income margin and consistent earnings beats. Recent news highlights AI-driven commerce initiatives and stablecoin partnerships, positioning the company for future growth. The stock is near its pivot point of $361, with support at $359 and resistance at $364.

The outlook remains positive with an 85% analyst buy rating and a $426.31 consensus price target, implying 18% upside. Risks include fintech competition and regulatory pressures, but Visa's robust cash flow and high profitability support long-term value. The next earnings report on April 28, 2026, will be a key catalyst.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About Visa Inc

Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.

Read more on V